I think is is way to early for a takeover at a reasonable share price that the shareholders would accept.
I am thinking that if the FDA has had visibility of the PMS Phase 2 results and they have similar efficacy as the pre-clinical mouse studies, then I am wondering if the FDA may have suggested a fast path for NNZ-2591 to get to PMS patients asap / quicker than planned. I am hoping this will be discussed on Monday as they results are announced.
Ann: Trading Halt, page-261
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
-0.310(1.54%) |
Mkt cap ! $2.538B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.45 | $19.74 | $4.663M | 234.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 507 | $19.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.89 | 765 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |